CN103052384B - 包含溴己新的含水组合物 - Google Patents

包含溴己新的含水组合物 Download PDF

Info

Publication number
CN103052384B
CN103052384B CN201180033796.5A CN201180033796A CN103052384B CN 103052384 B CN103052384 B CN 103052384B CN 201180033796 A CN201180033796 A CN 201180033796A CN 103052384 B CN103052384 B CN 103052384B
Authority
CN
China
Prior art keywords
composition
cough
present
bromhexine
preservative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180033796.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103052384A (zh
Inventor
U.舒林
B.普罗曼
A.赞波尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063562&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103052384(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN103052384A publication Critical patent/CN103052384A/zh
Application granted granted Critical
Publication of CN103052384B publication Critical patent/CN103052384B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN201180033796.5A 2010-07-12 2011-07-07 包含溴己新的含水组合物 Active CN103052384B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169236.6 2010-07-12
EP10169236 2010-07-12
PCT/EP2011/061527 WO2012007352A1 (de) 2010-07-12 2011-07-07 Wässrige zusammensetzung enthaltend bromhexin

Publications (2)

Publication Number Publication Date
CN103052384A CN103052384A (zh) 2013-04-17
CN103052384B true CN103052384B (zh) 2017-04-05

Family

ID=43063562

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180033796.5A Active CN103052384B (zh) 2010-07-12 2011-07-07 包含溴己新的含水组合物

Country Status (26)

Country Link
US (1) US9220693B2 (hu)
EP (1) EP2593094B1 (hu)
JP (1) JP5979763B2 (hu)
KR (1) KR101943812B1 (hu)
CN (1) CN103052384B (hu)
AR (1) AR082381A1 (hu)
AU (1) AU2011278451B2 (hu)
BR (1) BR112013000537B1 (hu)
CA (1) CA2803471C (hu)
CL (1) CL2012003625A1 (hu)
CO (1) CO6680609A2 (hu)
CY (1) CY1120079T1 (hu)
DK (1) DK2593094T3 (hu)
EA (1) EA025640B1 (hu)
EC (1) ECSP13012384A (hu)
ES (1) ES2661973T3 (hu)
HR (1) HRP20180396T1 (hu)
HU (1) HUE038399T2 (hu)
LT (1) LT2593094T (hu)
MX (1) MX337454B (hu)
PE (1) PE20131063A1 (hu)
PL (1) PL2593094T3 (hu)
PT (1) PT2593094T (hu)
SG (1) SG187016A1 (hu)
SI (1) SI2593094T1 (hu)
WO (1) WO2012007352A1 (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2593094B1 (de) 2010-07-12 2017-12-06 Sanofi-Aventis Deutschland GmbH Wässrige zusammensetzung enthaltend bromhexin
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
CN104350041A (zh) 2012-05-07 2015-02-11 塞利克斯比奥私人有限公司 用于治疗神经系统疾病的组合物和方法
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
EP2852570B1 (en) 2012-05-23 2020-04-22 Cellixbio Private Limited Composition for the treatment of inflammatory bowel disease
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
JP6017249B2 (ja) * 2012-09-28 2016-10-26 小林製薬株式会社 経口投与用液体医薬組成物
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN103893116B (zh) * 2014-04-17 2015-12-09 河北仁合益康药业有限公司 一种盐酸溴己新口服液组合物
CN116459204A (zh) * 2014-05-23 2023-07-21 勃林格殷格翰国际有限公司 含有盐酸氨溴索的咳嗽糖浆
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
CA2965449C (en) 2014-10-27 2020-11-10 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
DK3242869T3 (da) 2015-01-06 2022-01-31 Cellix Bio Private Ltd Sammensætninger og fremgangsmåder til behanding af inflammation og smerte
CN111568861A (zh) * 2020-05-25 2020-08-25 河北科星药业有限公司 畜禽用盐酸溴己新口服液及其制备方法和应用
CN111714477B (zh) * 2020-07-23 2021-06-15 山东迅达康兽药有限公司 祛痰组合物及其口服液制备方法
CN113109463B (zh) * 2021-03-16 2022-11-25 浙江工业大学 一种复方氯丙那林溴己新胶囊中有关物质的检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1396834A (zh) * 2000-01-31 2003-02-12 新药物研究瑞典股份公司 含有抗生素和祛痰药的稳定药物组合物及其制备方法
CN1564679A (zh) * 2001-10-10 2005-01-12 宝洁公司 包括愈创木酚甘油醚和聚氧化烯嵌段共聚物的口服液体组合物
CN101019826A (zh) * 2007-04-06 2007-08-22 张嵩 含有溴已新盐的组合物及大容量注射剂和注射剂制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085784B2 (ja) 1987-06-17 1996-01-24 興和株式会社 シロツプ剤
US5624906A (en) * 1994-12-08 1997-04-29 Lever Brothers Company, Division Of Conopco, Inc. Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds
EP0896815A4 (en) * 1996-05-02 2000-02-09 Taisho Pharmaceutical Co Ltd SUSPENSION OF A LITTLE WATER-SOLUBLE ACID MEDICINE
JP3800437B2 (ja) 1996-07-24 2006-07-26 大正製薬株式会社 苦味が軽減された液剤
JPH10101581A (ja) 1996-09-26 1998-04-21 Taisho Pharmaceut Co Ltd 塩酸ブロムヘキシンの安定化製剤及び安定化方法
JPH10306038A (ja) 1997-05-07 1998-11-17 Taisho Pharmaceut Co Ltd ブロムヘキシン含有液剤
JP2000281562A (ja) * 1999-03-30 2000-10-10 Taisho Pharmaceut Co Ltd ゲル状組成物
JP2001106639A (ja) * 1999-10-04 2001-04-17 Taisho Pharmaceut Co Ltd 経口用組成物
JP2002081562A (ja) 2000-09-05 2002-03-22 Kayaba Ind Co Ltd リリーフ弁
US6692725B2 (en) * 2001-02-19 2004-02-17 Daicel Chemical Industries, Ltd. Composition for oral care
JP5134802B2 (ja) * 2005-09-29 2013-01-30 第一三共ヘルスケア株式会社 塩酸ブロムヘキシン含有量低下の防止方法
US10022339B2 (en) * 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
JP2008013542A (ja) * 2006-06-07 2008-01-24 Daiichi Sankyo Healthcare Co Ltd 去痰又は気道杯細胞過形成抑制のための医薬組成物
KR101025498B1 (ko) * 2008-05-02 2011-03-31 (주)이엘티사이언스 염산브롬헥신 경구용 액제 복합조성물 및 그 제조방법
EP2593094B1 (de) 2010-07-12 2017-12-06 Sanofi-Aventis Deutschland GmbH Wässrige zusammensetzung enthaltend bromhexin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1396834A (zh) * 2000-01-31 2003-02-12 新药物研究瑞典股份公司 含有抗生素和祛痰药的稳定药物组合物及其制备方法
CN1564679A (zh) * 2001-10-10 2005-01-12 宝洁公司 包括愈创木酚甘油醚和聚氧化烯嵌段共聚物的口服液体组合物
CN101019826A (zh) * 2007-04-06 2007-08-22 张嵩 含有溴已新盐的组合物及大容量注射剂和注射剂制备方法

Also Published As

Publication number Publication date
AU2011278451A1 (en) 2013-01-24
SI2593094T1 (en) 2018-04-30
HRP20180396T1 (hr) 2018-04-20
EP2593094A1 (de) 2013-05-22
CY1120079T1 (el) 2018-12-12
US9220693B2 (en) 2015-12-29
MX337454B (es) 2016-03-07
PE20131063A1 (es) 2013-10-12
KR20130100091A (ko) 2013-09-09
ECSP13012384A (es) 2013-03-28
SG187016A1 (en) 2013-02-28
AU2011278451B2 (en) 2014-11-27
PL2593094T3 (pl) 2018-05-30
LT2593094T (lt) 2018-03-26
AR082381A1 (es) 2012-12-05
PT2593094T (pt) 2018-03-12
EA201201659A1 (ru) 2013-06-28
DK2593094T3 (en) 2018-03-12
CA2803471A1 (en) 2012-01-19
BR112013000537B1 (pt) 2021-07-27
CL2012003625A1 (es) 2013-05-31
JP2013531017A (ja) 2013-08-01
MX2013000417A (es) 2013-02-07
BR112013000537A2 (pt) 2016-05-24
US20130267605A1 (en) 2013-10-10
CA2803471C (en) 2019-01-15
KR101943812B1 (ko) 2019-01-31
ES2661973T3 (es) 2018-04-04
JP5979763B2 (ja) 2016-08-31
HUE038399T2 (hu) 2018-10-29
EA025640B1 (ru) 2017-01-30
CO6680609A2 (es) 2013-05-31
WO2012007352A1 (de) 2012-01-19
CN103052384A (zh) 2013-04-17
EP2593094B1 (de) 2017-12-06

Similar Documents

Publication Publication Date Title
CN103052384B (zh) 包含溴己新的含水组合物
JP2013543889A (ja) フランカルボン酸モメタゾン及び塩酸アゼラスチンを含む鼻内投与用医薬組成物
CN107823131A (zh) 用于口服的溶液
EP1181018B1 (en) Ziprasidone suspension
JP2523428B2 (ja) 消炎鎮痛ゲル製剤
WO2015047762A1 (en) Composition for application to a mucosa comprising a cellulose ether
EP3072515B1 (en) Pharmaceutical composition of sildenafil citrate in the form of a suspension for oral use
CN107714644B (zh) 口服使用的悬浮液形式的枸橼酸西地那非的药物组合物
CN106456706B (zh) 稳定化的去氨加压素
US7175855B1 (en) Ziprasidone suspension
WO2013062497A1 (en) Liquid pharmaceutical formulations
US6239165B1 (en) Liquid pharmaceutical formulation containing zotepine
CN105263524A (zh) 无染料的液体治疗溶液
CN111467305A (zh) 呋塞米口服溶液及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1178464

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1178464

Country of ref document: HK